Last reviewed · How we verify

DTaP-IPV-Hib-HepB vaccine

Sanofi Pasteur, a Sanofi Company · Phase 3 active Biologic

DTaP-IPV-Hib-HepB vaccine is a vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and hepatitis B in infants and children. Also known as: Hexaxim®.

This combination vaccine stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and hepatitis B pathogens.

This combination vaccine stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and hepatitis B pathogens. Used for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and hepatitis B in infants and children.

At a glance

Generic nameDTaP-IPV-Hib-HepB vaccine
Also known asHexaxim®
SponsorSanofi Pasteur, a Sanofi Company
Drug classvaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

DTaP-IPV-Hib-HepB is a hexavalent vaccine containing inactivated toxoids (diphtheria and tetanus), inactivated pertussis antigens, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B surface antigen. Upon administration, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory cells against all six pathogens.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTaP-IPV-Hib-HepB vaccine

What is DTaP-IPV-Hib-HepB vaccine?

DTaP-IPV-Hib-HepB vaccine is a vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and hepatitis B in infants and children.

How does DTaP-IPV-Hib-HepB vaccine work?

This combination vaccine stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and hepatitis B pathogens.

What is DTaP-IPV-Hib-HepB vaccine used for?

DTaP-IPV-Hib-HepB vaccine is indicated for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and hepatitis B in infants and children.

Who makes DTaP-IPV-Hib-HepB vaccine?

DTaP-IPV-Hib-HepB vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

Is DTaP-IPV-Hib-HepB vaccine also known as anything else?

DTaP-IPV-Hib-HepB vaccine is also known as Hexaxim®.

What drug class is DTaP-IPV-Hib-HepB vaccine in?

DTaP-IPV-Hib-HepB vaccine belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is DTaP-IPV-Hib-HepB vaccine in?

DTaP-IPV-Hib-HepB vaccine is in Phase 3.

What are the side effects of DTaP-IPV-Hib-HepB vaccine?

Common side effects of DTaP-IPV-Hib-HepB vaccine include Injection site reactions (pain, redness, swelling), Fever, Irritability, Drowsiness, Loss of appetite.

Related